Urine markers with special regard to fluorescent in situ hybridization (FISH);Uringebundene Marker mit besonderer Berücksichtigung der Fluoreszenz-in-situ-Hybridisierung (FISH)

Urologe - Ausgabe A

Volumn 50, Issue 3, 2011, Pages 297-302

  Lindemann Docter, K ^a   Gaisa, N T ^a   Smeets, D ^a   Knuchel Clarke R ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Fluorescent in situ hybridization; Molecular pathology; Noninvasive diagnosis; Urine diagnostics; Urothelial cancer

Indexed keywords

ARTICLE; BLADDER CANCER; CANCER PATIENT; CELL NUCLEUS; CENTROMERE; CYSTOSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE LOCUS; HUMAN; INTERPHASE; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; URINE; URINE CYTOLOGY;

HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 79955721004     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-010-2411-8     Document Type: Article

References (12)

1. Bubendorf L, Dalquen S, Savic S (2009) Zytologie der ableitenden Harnwege. Pathologe 30(Suppl 2):173-178
2. Dreicer R, Li H, Stein M et al (2009) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115:4090-4095
3. Fritsche HM, Burger M, Dietamier W et al (2010) Multicolor FISH (UroVysion) facilitates follow.up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 134:597-603
4. Knüchel R, Lindemann-Docter K (2009) Urinbasierte Tumordiagnostik des Harnblasenkarzinoms. Auswirkungen der neuen histopathologischen Klassifikation - Ein Denkanstoß. Urologe 48:598-608
5. Lae M, Couturier J, Oudard S et al (2010) Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21:815-819
6. Mian C, Mazzoleni G, Vikoler S et al (2010) Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours. Eur Urol 58:288-292
7. Vysis (2010) Produktinformation Vysis®: UroVysion Bladder Cancer Recurrence Kit. Vysis Inc., Abbott Park, Ill.
8. Pruthi RS, Nielsen M, Heathcote S et al (2010) A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJUI 106:349-356
9. Sarosdy MF, Kahn PR, Ziffer MD et al (2006) Use of multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176:44-47 (Pubitemid 43833178)
10. Schwarz S, Rechenmacher M, Filbeck T et al (2008) Value of multicolor fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions. J Clin Pathol 61:272-277 (Pubitemid 351354228)
11. Standard Operation Procedure (SOP) Fluoreszenz-in-situ-Hybridisierung UroVysion (2010) Institut für Pathologie, Universitätsklinik Aachen, RWTH Aachen
12. Volpe A, Racioppi M, D'Agostino D et al (2008) Bladder tumor markers: a review of the literature. Int J Biol Markers 23:249-261